About: Fulranumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Fulranumab is a monoclonal antibody against nerve growth factor. It was designed for the treatment of pain. Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.

Property	Value
dbo:abstract	فولرانوماب هو جسم مضاد وحيد النسيلة بشري مصمم لعلاج الألم، طورته جونسون وجونسون. (ar) Fulranumab is a monoclonal antibody against nerve growth factor. It was designed for the treatment of pain. Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain. (en)
dbo:casNumber	902141-80-4
dbo:fdaUniiCode	0E986JU40I
dbo:kegg	D09907
dbo:wikiPageID	33024009 (xsd:integer)
dbo:wikiPageLength	3958 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1082990296 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Amgen dbr:Nerve_growth_factor dbr:Johnson_&_Johnson dbr:List_of_investigational_analgesics dbr:Monoclonal_antibodies dbr:Amgen
dbp:atcPrefix	none (en)
dbp:c	6446 (xsd:integer)
dbp:casNumber	902141 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9930 (xsd:integer)
dbp:kegg	D09907 (en)
dbp:mabType	mab (en)
dbp:n	1718 (xsd:integer)
dbp:o	2018 (xsd:integer)
dbp:s	50 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:Nerve_growth_factor
dbp:type	mab (en)
dbp:unii	0 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	458274903 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Analgesic-stub dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Use_dmy_dates dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Growth_factor_receptor_modulators dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Amgen
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAnalgesics dbo:MonoclonalAntibody yago:Agent114778436 yago:Analgesic102707683 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:WikicatDrugs
rdfs:comment	فولرانوماب هو جسم مضاد وحيد النسيلة بشري مصمم لعلاج الألم، طورته جونسون وجونسون. (ar) Fulranumab is a monoclonal antibody against nerve growth factor. It was designed for the treatment of pain. Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain. (en)
rdfs:label	فولرانوماب (ar) Fulranumab (en)
owl:sameAs	freebase:Fulranumab yago-res:Fulranumab wikidata:Fulranumab dbpedia-ar:Fulranumab dbpedia-fa:Fulranumab https://global.dbpedia.org/id/4jwXb
prov:wasDerivedFrom	wikipedia-en:Fulranumab?oldid=1082990296&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Fulranumab
is dbo:wikiPageWikiLink of	dbr:List_of_investigational_analgesics dbr:List_of_therapeutic_monoclonal_antibodies
is foaf:primaryTopic of	wikipedia-en:Fulranumab